Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $653140.7.

  • Innate Pharma's Other Non-Current Assets rose 61353.85% to $653140.7 in Q2 2025 from the same period last year, while for Jun 2025 it was $653140.7, marking a year-over-year increase of 61353.85%. This contributed to the annual value of $622344.5 for FY2024, which is 56129.87% up from last year.
  • Innate Pharma's Other Non-Current Assets amounted to $653140.7 in Q2 2025, which was up 61353.85% from $614442.3 recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Other Non-Current Assets registered a high of $653140.7 during Q2 2025, and its lowest value of $91535.5 during Q2 2024.
  • In the last 5 years, Innate Pharma's Other Non-Current Assets had a median value of $158991.4 in 2022 and averaged $253287.3.
  • Per our database at Business Quant, Innate Pharma's Other Non-Current Assets crashed by 9982.06% in 2021 and then skyrocketed by 61353.85% in 2025.
  • Quarter analysis of 5 years shows Innate Pharma's Other Non-Current Assets stood at $169307.7 in 2021, then fell by 10.21% to $152016.8 in 2022, then crashed by 38.42% to $93606.8 in 2023, then surged by 556.41% to $614442.3 in 2024, then rose by 6.3% to $653140.7 in 2025.
  • Its last three reported values are $653140.7 in Q2 2025, $614442.3 for Q4 2024, and $91535.5 during Q2 2024.